Merck & Co (MRK)
$126.45
0.60 (0.48%)
MRK Stock Quote Delayed 30 Minutes
Merck & Co (MRK) a Sell on Falling Industry Group Rank
Portfolio Grader currently ranks Merck & Co (NYSE:MRK) a Sell. The approach to investing incorporated in this analytical tool developed by Louis Navellier assesses and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. MRK has maintained this ranking for the last month.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
320.09B
PE Ratio
140.50
EPS
0.9
Volume (Avg. Vol.)
6.79M
Day's Range
$124.91 - $126.60
52-Week Range
$99.14 - $134.63
Dividend & Yield
$2.92 (2.31%)
MRK Stock Predictions, Articles, and Merck & Co News
Merck & Co., Inc. (MRK) Takes a Hit After Q3 Loss
Merck (MRK) stock took a hit on Friday following a poor sowing in its earnings report for the third quarter of the year.
Falling Sales Growth Makes Merck & Co (MRK) a Sell
Currently, Merck & Co (NYSE:MRK) has a Sell using Louis Navellier's investing methodology and his Portfolio Grader stock evaluator. MRK has recently seen its Portfolio Grader rating downgraded over the last month from a Hold to a Sell.
Buy the Dip in Amgen, Inc. While Wall Street Fears It
Biotech falling knives like Amgen are notoriously dangerous, but AMGN stock has value against which I am willing to bet bullish.
Quant Score Keeps Merck & Co (MRK) a Sell
The current recommendation of Sell for Merck & Co (NYSE:MRK) has been derived by using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing methods. MRK has recently seen its Portfolio Grader rating downgraded over the last month from a Hold to a Sell.
Merck & Co’s (MRK) Raised to Hold
Merck & Co (NYSE:MRK) is ranked as a Hold using Louis Navellier's Portfolio Grader stock evaluator, which incorporates his investing methodology. The current overall Portfolio Grader recommendation on the shares has changed twice in the past month, which represents a greater level of change than is typical.
Buy Bristol-Myers Squibb Co (BMY) Stock With No Fear
BMY is rallying on solid fundamentals to reclaim a long-term pivot levels as support for even higher prices. Go long on strong support.
Supercharge Your Portfolio With Amgen, Inc. (AMGN) Stock
Wall Street goes on buying sprees into the biotech sector. Take advantage of this run to profit from red hot AMGN Stock. It's headed higher.
The Bull Case for Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Weak
VRX stock has rebounded off single-digit levels earlier this year, but the bull case for Valeant Pharmaceuticals remains flimsy.
Trump Lashes Out at Merck & Co., Inc. (MRK), But Does It Matter?
President Trump's tweet decrying Merck CEO Kenneth Frazier for quitting his manufacturing council couldn't dent MRK stock. But all isn't well.
3 Big Stock Charts for Friday: iShares Russell 2000 Index (ETF) (IWM), Goldman Sachs Group Inc (GS) and Merck & Co., Inc. (MRK)
iShares Russell 2000 Index (IWM), Goldman Sachs (GS) and Merck (MRK) are giving clear indications on where traders need to buy and sell this market.
Gilead Sciences, Inc. (GILD) Stock Is a 2-for-1 Deal
Gilead's two segments can confuse investors. GILD stock provides access to a shrinking HCV franchise ... but also a growing HIV drug biz.
AbbVie Inc (ABBV) Stock Isn’t Done Charting New Highs Yet
Pharma is a fast moving sector and the doors close quickly. With AbbVie's (ABBV) door open, sell ABBV stock puts now!
Amgen, Inc. (AMGN) Stock Is the Cure for Ailing Portfolios
Sell risk in Amgen (AMGN) while elevated levels of biotech nervousness throw a fog around AMGN stock fundamentals.
3 Big Stock Charts for Thursday: Merck & Co., Inc. (MRK), Gilead Sciences, Inc. (GILD) and Valeant Pharmaceuticals Intl Inc (VRX)
Merck (MRK), Gilead (GILD) and Valeant (VRX) stock are all making notable moves today. Here's what you need to know.
Petya Ransomware Attack: List of Companies Hit in Latest Hack
The world is facing an attack from a new version of the Petya ransomware and many companies have already been hit by the virus.
How We Earn $5,300 In Dividends From A $10,000 Investment (VZ, PSX, GILD)
It's the most lucrative investing strategy I've ever found: create a portfolio of dividend stocks that generate as many as 30 checks a month
3 Stocks to Watch on Tuesday: Shopify Inc (US) (SHOP), Under Armour Inc (UAA) and Merck & Co., Inc. (MRK)
Shopify's (SHOP) hot run is hitting a wall, Merck & Co. (MRK) stumbles on a trial misstep and Under Armour (UAA) is heating up.
